Kyle C J, Petersen H E, Overø K F
Depress Anxiety. 1998;8(4):147-53.
The enhanced sensitivity of the elderly to the side effects produced by tricyclic antidepressants (TCAs), and the frequency and type of adverse events, have made the treatment of depression in this group difficult. The selective serotonin reuptake inhibitors (SSRIs) have been reported to produce significantly fewer undesirable side effects and display better tolerance than TCAs. We compared the therapeutic actions and side effects produced by citalopram, the most selective SSRI available, with amitriptyline in a group of elderly patients (aged 65 and older) diagnosed with major depression. In a double-blind, double-dummy, parallel-group, multicenter comparison of citalopram (20 or 40 mg/day) and amitriptyline (50 or 100 mg/day), patients who did not respond to placebo during a 1-week single-blind phase were randomly assigned to receive citalopram or amitriptyline for 8 weeks. Efficacy measures included the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Scale (HAMD), and Clinical Global Impressions. Both drug treatments produced equivalent time-related declines in severity of depression, so that by 8 weeks slightly more than 50% of the patients in each group experienced marked recovery, defined as MADRS scores < or = 12. Amitriptyline produced a greater overall incidence of adverse events, including a significantly higher (P < 0.001) percentage of patients reporting dry mouth (34% vs. 7%), as well as a significantly higher (P < 0.02) incidence of somnolence. Constipation and fatigue also occurred more frequently in the amitriptyline than in the citalopram group. For only one event (nausea) did the citalopram group report a significantly greater (P = 0.012) incidence (12.8% vs. 4.8%). On the basis of these results, it was concluded that citalopram is as effective an antidepressant as amitriptyline in the treatment of the depressed elderly. Because of its low incidence and low magnitude of side effects, citalopram seems especially useful in private practice.
老年人对三环类抗抑郁药(TCA)产生的副作用敏感性增强,以及不良事件的频率和类型,使得该群体的抑郁症治疗变得困难。据报道,选择性5-羟色胺再摄取抑制剂(SSRI)产生的不良副作用明显较少,且耐受性优于TCA。我们在一组被诊断为重度抑郁症的老年患者(65岁及以上)中,比较了最具选择性的SSRI西酞普兰与阿米替林的治疗作用和副作用。在西酞普兰(20或40毫克/天)与阿米替林(50或100毫克/天)的双盲、双模拟、平行组、多中心比较中,在1周单盲阶段对安慰剂无反应的患者被随机分配接受西酞普兰或阿米替林治疗8周。疗效指标包括蒙哥马利-阿斯伯格抑郁评定量表(MADRS)、汉密尔顿抑郁量表(HAMD)和临床总体印象。两种药物治疗在抑郁症严重程度方面产生了与时间相关的等效下降,因此到8周时,每组略多于50%的患者经历了显著康复,定义为MADRS评分≤12。阿米替林产生的不良事件总体发生率更高,包括报告口干的患者百分比显著更高(P<0.001)(34%对7%),以及嗜睡发生率显著更高(P<0.02)。便秘和疲劳在阿米替林组中也比西酞普兰组更频繁发生。只有一种事件(恶心)西酞普兰组报告的发生率显著更高(P = 0.012)(12.8%对4.8%)。基于这些结果,得出结论:在治疗老年抑郁症患者方面,西酞普兰作为抗抑郁药与阿米替林一样有效。由于其副作用发生率低且程度轻,西酞普兰在私人诊所似乎特别有用。